SEQENS, a manufacturer of active ingredients and pharmaceutical intermediates, is making a multi-million-dollar investment in its R&D lab in Devens, MA. The improvements aim to ensure the new facility will operate at the highest standards of safety and quality, and increase R&D capability and productivity in the U.S. The project is expected to be complete in October 2022.
 
The investment in Devens strengthens the company’s U.S. operations—which also includes a sales office and contract development and manufacturing operation in Newburyport, MA. The investment comes three months after SK Capital became a majority holder in SEQENS by merging it with its portfolio company Wavelength Pharmaceuticals to create one of the largest, and most diversified CDMOs.
 
“With the support of our shareholders and with the combination of Wavelength’s technologies, products, and recognized know-how, we will accelerate the projects launched in recent months and further strengthen our positions to support our customers worldwide in the development of their projects,” said Pierre Luzeau, President of SEQENS.
 
The addition of Wavelength broadens SEQENS’ global reach by providing production facilities in Israel and India and sales offices in Europe and the U.S. It also broadens SEQENS’ API portfolio and its cytotoxic, steroidal, and high-potency products, along with Wavelength’s expertise in complex pharmaceutical synthesis. In total, the expanded portfolio now includes 200 active pharmaceutical ingredients (APIs), 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.
 
In addition, SEQENS is investing significantly across the enterprise to support customers’ growth in both its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high potency APIs, and biocatalysts.